Lesion based diagnostic performance of dual phase (99m)Tc-MIBI SPECT/CT imaging and ultrasonography in patients with secondary hyperparathyroidism

双相(99m)Tc-MIBI SPECT/CT显像和超声检查在继发性甲状旁腺功能亢患者中的病灶诊断性能

阅读:1

Abstract

BACKGROUND: We aimed to evaluate the diagnostic performance of (99m)Tc-MIBI SPECT/CT and ultrasonography in patients with secondary hyperparathyroidism (SHPT), and explored the factors that affect the diagnostic performance. METHODS: (99m)Tc-MIBI SPECT/CT and ultrasonography were performed in 50 patients with SHPT within 1 month before they underwent surgery. Imaging results were confirmed by the pathology. Pearson correlation analysis was used to determine the correlation of PTH level with clinical data. The optimal cutoff value for predicting positive (99m)Tc-MIBI results was evaluated by ROC analysis in lesions diameter. RESULTS: Forty-nine patients had a positive (99m)Tc-MIBI imaging results and 39 patients had positive ultrasonography results. The sensitivities of (99m)Tc-MIBI and ultrasonography were 98.00% and 78.00%, respectively. A total of 199 lesions were resected in 50 patients. Among them, 183 lesions were proved to be parathyroid hyperplasia. On per-lesion basis analysis, the sensitivity and specificity of (99m)Tc-MIBI and ultrasonography were 59.34% and 75.00% vs 46.24% and 80.00%, respectively. The Pearson correlation analysis showed that the serum AKP and PTH level had a significant linear association (r = 0.699, P < 0.001). The lesion diameter was a statistically significant predictive factor in predicting positive (99m)Tc-MIBI SPECT/CT. The optimal cutoff value for predicting positive (99m)Tc-MIBI results evaluated by ROC analysis in lesions diameter was 8.05 mm. CONCLUSION: Dual phase (99m)Tc-MIBI SPECT/CT imaging had a higher sensitivity in patients with SHPT than ultrasonography. Therefore, using (99m)Tc-MIBI positioning the lesion could be an effective method pre-surgical in patients with SHPT.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。